Uplifting message in 3 photos (2023)

CAMBRIDGE, Mass. & KAWASAKI, KANAGAWA, Japan--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ), a leader in RNAi therapeutics, and PeptiDream, Inc. .(TSE: 4587), a leading peptide-based drug discovery company and its Peptide Discovery Platform System (PDPS), today announced a licensing and collaboration agreement to discover and develop peptide siRNAs to create additional opportunities to Extrahepatic tissues deliver RNAi therapy. .Through this collaboration, the companies will jointly select and optimize peptides for the targeted delivery of small RNA interference (siRNA) to a variety of cell types and tissues through targeted interactions with receptors expressed on target cells.

Under the terms of the alliance, Alnylam will select a group of recipients for PeptiDream's peptide discovery platform. PeptiDream will select, optimize and synthesize peptides for each receptor. Will Alnylam then generate the peptide-siRNA conjugate and execute it?in vitro? Yeah?direct• Studies to support the final selection of peptides. By targeting disease-causing mRNA transcripts in a variety of different tissue types, the collaboration has the potential to generate additional therapeutic options. After solving the delivery problem of RNAi therapeutics to the liver and making major preclinical progress?direct? We are now adding delivery to the central nervous system, eye and lungs to our suite of delivery technologies that have the potential to enable effective delivery of siRNA to a wider range of tissue types throughout the human body? said Dr. Kevin Fitzgerald, Alnylam's chief scientific officer. "We are pleased to enter into this research collaboration agreement with PeptiDream, an industry leader in the discovery and optimization of peptide ligands for multiple receptors. Through this collaboration, we hope to identify robust ligands for extrahepatic tissue delivery -receptor pair, similar to the GalNAc-ASGPR pair, we have pioneered highly efficient liver delivery "This agreement further expands our use of peptides to deliver multiple therapeutic payloads to diseased cells (e.g. peptide-drug conjugates) strategy. /tissue is targeted. We hope this partnership will lead to the creation of innovative peptide-siRNA conjugates in multiple diseases and unlock many new therapeutic opportunities. Under the terms of the agreement, PeptiDream will receive an upfront payment from Alnyam as well as research and development funding during the term. Research collaborations as stipulated in the agreement. PeptiDream may also receive payments depending on the achievement of certain development, regulatory and commercial milestones, which may amount to up to DKK 2.2 billion. US dollars ($244 billion^*1). In addition, PeptiDream is entitled to receive low to mid single digit royalties on the sale of these Alnylam products. *1: USD/JPY exchange rate: 110.9About RNAiRNAi (RNA interference), a natural cellular gene silencing process, represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Their discovery has been hailed as "a major scientific breakthrough that occurs about every ten years"? And won the 2006 Nobel Prize in Physiology or Medicine. By harnessing the natural biological process of RNAi that occurs in our cells, a new class of medicines called RNAi therapeutics is now a reality. Small RNA interference (siRNA), the molecule that mediates RNAi and constitutes Alnylam's RNAi therapeutics platform, works upstream of current drugs by effectively silencing messenger RNA (mRNA)? genetic precursor? They encode disease-causing proteins, which prevent them from happening. It's a revolutionary approach that has the potential to change the treatment of patients with genetic and other disorders.Om Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardiometabolic, infectious liver and central nervous system diseases. (CNS) / eye disease. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful and clinically proven approach to treating a variety of serious and debilitating diseases. Founded in 2002, Alnyam has a bold vision to turn scientific opportunity into reality through a powerful RNAi therapeutics platform. Alnylam's commercial RNAi therapy is ONPATTRO? (patisirán), GIVLAARI? (givosiran), OXLUMO? (lumasiran) and Leqvio? (inclisiran) is developed and marketed by Alnylam's partner Novartis. Alnylam has a large pipeline of investigational drugs, including six late-stage drug candidates. Alnylam rides on its ?Alnylam P⁵x25? A leading biotech profile with a strategy to deliver transformative medicines for rare and common diseases, benefiting patients worldwide through sustainable innovation and superior financial performance. Alnylam is headquartered in Cambridge, Massachusetts. To learn more about our people, science and pipeline, visit ?www.alnylam.com? And engage with us on Twitter?@Alnylam, I?LinkedIn, Yes?instagram.Om PeptiDream, Inc.PeptiDream, Inc., a publicly traded biopharmaceutical company (TSE: 4587) founded in 2006, has deployed its own Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform capable of producing non-peptide discovery platform systems Standard high potency peptides are used to identify high potency and selectivity successful candidates, which can then be developed into peptide, small molecule or peptide-drug conjugate based therapies. PeptiDream strives to be a world leader in the discovery and development of medicines to address unmet medical needs and improve the quality of life of patients worldwide. For more information, please visit ?https://www.peptiddream.com.Alnylam Forward-Looking StatementsVarious statements in this press release relate to Alnylam's expectations, plans, aspirations and goals, including statements related to PeptiDream's license and collaboration agreement, and the discovery and development of powerful siRNA-peptide conjugates to create additional opportunities to incorporate RNAi The ability of the therapy to deliver to a broad population of non-liver tissue types, the potential for future milestone and royalty payments to PeptiDream and the planned acquisition of our ?Alnylam P⁵x25? strategy, which constitutes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated in these forward-looking statements due to a variety of significant risks, uncertainties, and other factors, including but not limited to: the global COVID-19 pandemic or any future pandemic The direct or indirect impact of the pandemic on the Company, Alnylam's operating results and financial condition, and the effectiveness or timeliness of Alnylam's efforts to mitigate the impact of the pandemic; Alnylam discovers and develops new drug candidates and methods of delivery and successfully demonstrates the efficacy and safety of its product candidates; the preclinical and clinical results of its product candidates; actions or recommendations by regulatory agencies, and Alnylam's ability to obtain and maintain regulatory approvals and favorable pricing and rebates for its product candidates; globally Successful launch, marketing and sale of its approved products; delays, interruptions or failures in manufacturing and delivery of its product candidates or their marketed products; acquisition, maintenance and protection of intellectual property rights; successful future expansion of ONPATTRO (or vutrisiran, if approved) by Alnylam Indication; Alnylam's ability to manage its growth and operating expenses through disciplined operating investments, and its ability to achieve a self-sustaining financial position without the need for equity financing in the future; Alnylam's ability to maintain strategic business partnerships; Alnylam's reliance on third parties proceed with the development and commercialization of certain products, including Novartis, Regeneron and Vir; trial results; risks of government investigations; and unexpected expenses; and risks discussed in more detail under "Risk Factors." Filed with Alnylam's most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and other filings with the SEC. In addition, any forward-looking statements represent Alnyam's views only as of today and should not be relied upon as its views at any time in the future. Alnylam specifically disclaims any obligation to update any forward-looking statement, except to the extent required by law.